Patient Selection for Pemafibrate Therapy to Prevent Adverse Cardiovascular Events

Background: pemafibrate is a newly-introduced selective peroxisome proliferator-activated receptor-α modulator, which decreases serum triglyceride levels with few drug-related adverse events and may reduce the risk of adverse cardiovascular events in carefully selected patients with hypertriglycerid...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumida, Toshihide, Imamura, Teruhiko, Narang, Nikhil, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821179/
https://www.ncbi.nlm.nih.gov/pubmed/36614823
http://dx.doi.org/10.3390/jcm12010021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821179/
https://www.ncbi.nlm.nih.gov/pubmed/36614823
http://dx.doi.org/10.3390/jcm12010021

Ejemplares similares